Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

详细信息    查看全文

• 作者：Verena Krähling ; Dirk Becker ; Cornelius Rohde…
• 关键词：Ebola virus ; ELISA ; Clinical diagnostics ; Ebola virus vaccination ; Seroconversion
• 刊名：Medical Microbiology and Immunology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：205
• 期：2
• 页码：173-183
• 全文大小：1,408 KB
• 参考文献：1.Kiley MP, Bowen ET, Eddy GA et al (1982) Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology 18:24–32CrossRef PubMed
  2.Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487–498CrossRef PubMed
  3.Sanchez A, Geisbert TW (2006) Feldmann H. Marburg and Ebola viruses. Fields virology, Filoviridae, pp 1409–1448
  4.Towner JS, Sealy TK, Khristova ML et al (2008) Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4:e1000212CrossRef PubMed PubMedCentral
  5.Falzarano D, Feldmann F, Grolla A et al (2011) Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 204(Suppl 3):S1082–S1089CrossRef PubMed PubMedCentral
  6.Wong G, Audet J, Fernando L et al (2014) Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32:5722–5729CrossRef PubMed
  7.Wong G, Richardson JS, Cutts T, Qiu X, Kobinger GP (2015) Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res 116:17–19. doi:10.​1016/​j.​antiviral.​2015.​01.​001 CrossRef PubMed
  8.Kanapathipillai R, Henao Restrepo AM, Fast P et al (2014) Ebola vaccine—an urgent international priority. N Engl J Med 371:2249–2251CrossRef PubMed
  9.Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS; the VRC 207 Study Team (2014) Chimpanzee adenovirus vector ebola vaccine—preliminary report. N Engl J Med. doi:10.​1056/​NEJMoa1410863 PubMed
  10.Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Krähling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV (2015) A monovalent chimpanzee adenovirus ebola vaccine—preliminary report. N Engl J Med. doi:10.​1056/​NEJMoa1411627 PubMed
  11.Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA (2015) Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. doi:10.​1056/​NEJMoa1502924
  12.WHO (2015) Ebola vaccines, therapies, and diagnostics. http://​www.​who.​int/​medicines/​emp_​ebola_​q_​as/​en/​ . Accessed 06 July 2015
  13.Huang Y, Zhu Y, Yang M, Zhang Z, Song D, Yuan Z (2014) Nucleoprotein-based indirect enzyme-linked immunosorbent assay (indirect ELISA) for detecting antibodies specific to Ebola virus and Marbug virus. Virol Sin 29:372–380CrossRef PubMed
  14.Ikegami T, Saijo M, Niikura M et al (2003) Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus. Epidemiol Infect 130:533–539PubMed PubMedCentral
  15.Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ (1999) ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 179(Suppl 1):S192–S198CrossRef PubMed
  16.Macneil A, Reed Z, Rollin PE (2011) Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis 5:e1175CrossRef PubMed PubMedCentral
  17.Nakayama E, Yokoyama A, Miyamoto H et al (2010) Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 17:1723–1728CrossRef PubMed PubMedCentral
  18.Saijo M, Niikura M, Morikawa S et al (2001) Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins. J Clin Microbiol 39:1–7CrossRef PubMed PubMedCentral
  19.Sobarzo A, Perelman E, Groseth A et al (2012) Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin Vaccine Immunol 19:1844–1852CrossRef PubMed PubMedCentral
  20.Wolf T, Kann G, Becker S et al (2015) Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385:1428–1435CrossRef PubMed
  21.Lucht A, Grunow R, Otterbein C, Möller P, Feldmann H, Becker S (2004) Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus. Med Microbiol Immunol 193:181–187CrossRef PubMed
  22.Pauly D, Chacana PA, Calzado EG, Brembs B, Schade R (2011) IgY technology: extraction of chicken antibodies from egg yolk by polyethylene glycol (PEG) precipitation. J Vis Exp 51:e3084. doi: 10.​3791/​3084
  23.Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177–182CrossRef PubMed PubMedCentral
  24.Baize S, Pannetier D, Oestereich L et al (2014) Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418–1425CrossRef PubMed
  25.Kreuels B, Wichmann D, Emmerich P et al (2014) A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 371:2394–2401CrossRef PubMed
  26.Günther S, Feldmann H, Geisbert TW et al (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204(Suppl 3):S785–S790CrossRef PubMed
  27.Kolesnikova L, Mittler E, Schudt G, Shams-Eldin H, Becker S (2012) Phosphorylation of Marburg virus matrix protein VP40 triggers assembly of nucleocapsids with the viral envelope at the plasma membrane. Cell Microbiol 14:182–197CrossRef PubMed
  28.Becker S, Feldmann H, Will C, Slenczka W (1992) Evidence for occurrence of filovirus antibodies in humans and imported monkeys: Do subclinical filovirus infections occur worldwide? Med Microbiol Immunol 181:43–55CrossRef PubMed
  29.Becquart P, Wauquier N, Mahlakõiv T et al (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE 5:e9126CrossRef PubMed PubMedCentral
  30.Boisen ML, Schieffelin JS, Goba A et al (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol 28:19–31CrossRef PubMed PubMedCentral
  31.Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW (2005) Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué–Ivindo region, Northeastern Gabon, 1997. J Infect Dis 191:964–968CrossRef PubMed
  32.Jacobson RH (1998) Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech 17:469–526PubMed
  33.Mire CE, Geisbert JB, Agans KN et al (2014) Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE 9:e94355CrossRef PubMed PubMedCentral
  34.Feldmann H, Klenk HD, Sanchez A (1993) Molecular biology and evolution of filoviruses. Arch Virol Suppl 7:81–100CrossRef PubMed
  35.Dornmair K, Kiefer H, Jähnig F (1990) Refolding of an integral membrane protein. OmpA of Escherichia coli. J Biol Chem 265:18907–18911PubMed
  
• 作者单位：Verena Krähling (1) (2)
  Dirk Becker (1) (2)
  Cornelius Rohde (1)
  Markus Eickmann (1) (2)
  Yonca Eroğlu (1) (2)
  Astrid Herwig (1)
  Romy Kerber (3)
  Katharina Kowalski (1)
  Júlia Vergara-Alert (1) (2)
  Stephan Becker (1) (2)
  the European Mobile Laboratory consortium
  
  1. Institute of Virology, Philipps University Marburg, Hans-Meerwein-Str 2, 35043, Marburg, Germany
  2. German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Hans-Meerwein-Str 2, 35043, Marburg, Germany
  3. Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Str. 74, 20359, Hamburg, Germany
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Immunology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1831

文摘

The 2014 Zaire Ebola virus (ZEBOV) outbreak in West Africa represents an international public health concern. Highly sensitive and precise diagnostic tools are needed. In the present study, we developed a ZEBOV-specific enzyme-linked immunosorbent assay (ELISA) using inactivated ZEBOV isolate Makona from March 2014. Mock antigen was used to address nonspecific binding. Specificity, reproducibility and precision were determined to measure assay performance. The ZEBOV ELISA proved to be specific (96 %), reproducible and precise (Intra-assay CV 8 %, Inter-assay CV 18 %). Using the human monoclonal antibody KZ52, we showed that the ELISA was able to detect conformation-specific antibodies. Monitoring antibody development in 29 PCR-positive EBOV disease (EVD) patients revealed seroconversion in all cases. In addition, the ELISA was used to detect ZEBOV glycoprotein (GP)-specific antibodies in a vaccinated volunteer from day 14 until 5 years post-vaccination with a VSV-ZEBOV candidate vaccine. The results demonstrate the high reproducibility, specificity and sensitivity of this newly developed ELISA, which is suitable for the detection of specific antibody responses directed against different ZEBOV proteins in EVD patients and against the ZEBOV surface glycoprotein GP in vaccinated individuals.